LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article ; Online: Fatal pancreatitis presenting as pancreatic panniculitis without enzyme elevation.

    Jacobson-Dunlop, Erick / Takiguchi, Rodd / White, Clifton R / White, Kevin P

    Journal of cutaneous pathology

    2011  Volume 38, Issue 6, Page(s) 455–457

    MeSH term(s) Amylases/blood ; Fatal Outcome ; Female ; Humans ; Lipase/blood ; Middle Aged ; Pancreatitis/blood ; Pancreatitis/complications ; Pancreatitis/pathology ; Panniculitis/etiology ; Panniculitis/pathology
    Chemical Substances Lipase (EC 3.1.1.3) ; Amylases (EC 3.2.1.-)
    Language English
    Publishing date 2011-06
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 187078-6
    ISSN 1600-0560 ; 0303-6987
    ISSN (online) 1600-0560
    ISSN 0303-6987
    DOI 10.1111/j.1600-0560.2011.01725_1.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1043: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Verrucous porokeratosis of the gluteal cleft (porokeratosis ptychotropica): a rare disorder easily misdiagnosed.

    Takiguchi, Rodd H / White, Kevin P / White, Clifton R / Simpson, Eric L

    Journal of cutaneous pathology

    2010  Volume 37, Issue 7, Page(s) 802–807

    Abstract: Porokeratosis represents a heterogeneous group of disorders characterized clinically by a distinctive ridge-like border and histologically by cornoid lamellae. A verrucous variant of porokeratosis involving the gluteal cleft has been recently described. ... ...

    Abstract Porokeratosis represents a heterogeneous group of disorders characterized clinically by a distinctive ridge-like border and histologically by cornoid lamellae. A verrucous variant of porokeratosis involving the gluteal cleft has been recently described. We present 5 new cases and review the current literature to highlight the clinical and histopathologic features of this disorder. Descriptive terms including hyperkeratotic porokeratosis, genitogluteal porokeratosis, porokeratoma, follicular porokeratosis, and porokeratosis ptychotropica have all been used to describe this verrucous variant of porokeratosis involving the gluteal cleft. To avoid further confusion, we propose a consolidation of terminologies and suggest verrucous porokeratosis be added to the commonly described variants of porokeratosis.
    MeSH term(s) Adult ; Buttocks/pathology ; Humans ; Male ; Middle Aged ; Pedigree ; Porokeratosis/pathology ; Rare Diseases ; Warts/pathology
    Language English
    Publishing date 2010-07
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 187078-6
    ISSN 1600-0560 ; 0303-6987
    ISSN (online) 1600-0560
    ISSN 0303-6987
    DOI 10.1111/j.1600-0560.2009.01387.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1043: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: CD30 expression on CD1a+ and CD8+ cells in atopic dermatitis and correlation with disease severity.

    Oflazoglu, Ezogelin / Simpson, Eric L / Takiguchi, Rodd / Grewal, Iqbal S / Hanifin, Jon M / Gerber, Hans-Peter

    European journal of dermatology : EJD

    2008  Volume 18, Issue 1, Page(s) 41–49

    Abstract: Atopic dermatitis (AD) is a chronic inflammatory skin disease associated with cutaneous hyperreactivity to environmental stimuli, resulting in increased infiltration of inflammatory cells, IgE production and enhanced expression of costimulatory molecules, ...

    Abstract Atopic dermatitis (AD) is a chronic inflammatory skin disease associated with cutaneous hyperreactivity to environmental stimuli, resulting in increased infiltration of inflammatory cells, IgE production and enhanced expression of costimulatory molecules, cytokines and chemokines. CD30, a TNF receptor superfamily member, is a costimulatory molecule expressed on activated T and B cells. A positive correlation between soluble CD30 (sCD30) levels in patient serum and AD disease severity has been described previously. However, the relative frequencies and identities of cells expressing CD30 in AD patients and the relationship between the frequency of CD30 positive cells and serum sCD30 levels with disease severity remained unknown. To address these questions, immunofluorescence analysis of AD skin lesions representing different disease stages, was conducted. In addition to the CD4+ T cells, CD1a+ Langerhans cells and CD8+ T cells were found to express CD30 in AD lesions and the cell numbers correlated with disease severity. FACS analysis of AD patient blood samples revealed expression of CD30 on memory T-cells and a correlation with disease severity was identified. Finally, serum analysis of soluble mediators revealed positive correlations between sCD30, IgE, MDC, TARC and PARC levels with disease severity. Combined, our data provide correlative evidence that CD30+ cells, including Langerhans cells and CD8+ T-cells, may contribute to AD disease severity and that therapeutic strategies targeting CD30+ cells may provide benefit to AD patients.
    MeSH term(s) Antigens, CD1/analysis ; CD4 Antigens/analysis ; CD8-Positive T-Lymphocytes/immunology ; Chemokine CCL17/blood ; Chemokines, CC/blood ; Dermatitis, Atopic/immunology ; Dermatitis, Atopic/pathology ; Humans ; Immunohistochemistry ; Interleukin-8/blood ; Ki-1 Antigen/analysis ; Ki-1 Antigen/blood ; Langerhans Cells/immunology ; Skin/immunology ; Skin/pathology
    Chemical Substances Antigens, CD1 ; CCL18 protein, human ; CD1a antigen ; CD4 Antigens ; Chemokine CCL17 ; Chemokines, CC ; Interleukin-8 ; Ki-1 Antigen
    Language English
    Publishing date 2008-01
    Publishing country France
    Document type Journal Article
    ZDB-ID 1128666-0
    ISSN 1952-4013 ; 1167-1122
    ISSN (online) 1952-4013
    ISSN 1167-1122
    DOI 10.1684/ejd.2008.0309
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3484: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: CD40 expression on antigen presenting cells and correlation with disease severity in atopic dermatitis.

    Oflazoglu, Ezogelin / Simpson, Eric L / Takiguchi, Rodd / Hanifin, Jon M / Grewal, Iqbal S / Gerber, Hans-Peter

    European journal of dermatology : EJD

    2008  Volume 18, Issue 5, Page(s) 527–533

    Abstract: Atopic dermatitis (AD) is a chronic inflammatory skin disease associated with cutaneous hyperreactivity to environmental stimuli, resulting in increased infiltration of inflammatory cells, IgE production and enhanced expression of various co-stimulatory ... ...

    Abstract Atopic dermatitis (AD) is a chronic inflammatory skin disease associated with cutaneous hyperreactivity to environmental stimuli, resulting in increased infiltration of inflammatory cells, IgE production and enhanced expression of various co-stimulatory molecules, Th2 cytokines and chemokines. Antigen presenting cells (APCs) are critical for AD disease pathogenesis and interaction between APCs and inflammatory T cells represents an important signal required for induction and maintenance of the inflammatory process. CD40 was shown to be upregulated on inflammatory cells in patients with atopic dermatitis; however the identity of these cells and their correlation with disease severity remained unknown. To address these questions, we determined CD40 expression in skin lesions and on peripheral blood cells from AD patients and identified a positive correlation between the numbers of CD40 positive cells and disease severity. Furthermore, we identified the nature of CD40 positive cells in skin lesions to include CD1a+ and CD11b+ APCs. Finally, a correlation between serum PARC and IgE levels and the numbers of CD40+ cells in AD skin lesions was found. Combined, these findings demonstrate that CD40 is upregulated on APCs, cell types previously shown to contribute to AD disease pathology, and suggest that therapeutic strategies targeting CD40 positive cells may provide benefit to AD patients.
    MeSH term(s) Antigen-Presenting Cells/immunology ; CD40 Antigens/biosynthesis ; Dermatitis, Atopic/immunology ; Humans ; Severity of Illness Index
    Chemical Substances CD40 Antigens
    Language English
    Publishing date 2008-09
    Publishing country France
    Document type Comparative Study ; Journal Article
    ZDB-ID 1128666-0
    ISSN 1952-4013 ; 1167-1122
    ISSN (online) 1952-4013
    ISSN 1167-1122
    DOI 10.1684/ejd.2008.0495
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3484: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Efalizumab for severe atopic dermatitis: a pilot study in adults.

    Takiguchi, Rodd / Tofte, Susan / Simpson, Brenda / Harper, Erin / Blauvelt, Andrew / Hanifin, Jon / Simpson, Eric

    Journal of the American Academy of Dermatology

    2007  Volume 56, Issue 2, Page(s) 222–227

    Abstract: Background: Severe atopic dermatitis (AD) often cannot be adequately controlled with topical agents. The continuous use of current systemic therapies for AD is limited by end-organ toxicities. A safe and effective systemic therapy for patients with ... ...

    Abstract Background: Severe atopic dermatitis (AD) often cannot be adequately controlled with topical agents. The continuous use of current systemic therapies for AD is limited by end-organ toxicities. A safe and effective systemic therapy for patients with recalcitrant AD is greatly needed.
    Objective: To evaluate the potential safety and efficacy of efalizumab, an inhibitor of T cell activation and migration, in adults with severe AD.
    Methods: An investigator-initiated, prospective, open-label, pilot study was conducted involving ten subjects with severe AD. Subjects received an initial conditioning subcutaneous dose of efalizumab of 0.7 mg/kg followed by 1.0 mg/kg weekly for another 11 weeks for a total of 12 doses. The primary efficacy outcome was the change in the mean Eczema Area and Severity Index (EASI) score from baseline as measured at week 12. Monitoring of adverse events continued for 8 weeks after discontinuation of therapy.
    Results: EASI scores improved from a mean baseline score of 37.1 +/- 13.5 to 17.6 +/- 14.5 at week 12 (52.3% improvement; P < .0001). Six out of ten subjects reached at least a 50% improvement in EASI score by week 12. Pruritus levels decreased from 6.9 cm +/- 1.8 cm to 4.9 cm +/- 2.5 cm utilizing a visual analogue score (P < .015). Overall, efalizumab was well tolerated. There were three significant adverse events during the course of this study, including thrombocytopenia, viral gastroenteritis, and a subject with worsening of disease beyond baseline levels after drug discontinuation.
    Limitations: It is difficult to apply these findings to larger populations of patients with AD because this study lacked a control group and involved a small number of subjects with very severe disease. Long-term efficacy and safety of efalizumab in this population is not known.
    Conclusions: Efalizumab therapy resulted in significant clinical improvements in six of ten subjects with severe AD. Efalizumab may serve as a good alternative to current systemic immunosuppressants used for AD; however, double-blind placebo-controlled studies are needed to test its efficacy and safety.
    MeSH term(s) Adult ; Anti-Inflammatory Agents/therapeutic use ; Antibodies, Monoclonal/therapeutic use ; CD11 Antigens/immunology ; Cell Migration Inhibition ; Dermatitis, Atopic/drug therapy ; Dermatitis, Atopic/immunology ; Humans ; Immunoglobulin E/blood ; Pilot Projects ; Prospective Studies ; Treatment Outcome
    Chemical Substances Anti-Inflammatory Agents ; Antibodies, Monoclonal ; CD11 Antigens ; Immunoglobulin E (37341-29-0) ; efalizumab (XX2MN88N5D)
    Language English
    Publishing date 2007-02
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 603641-7
    ISSN 1097-6787 ; 0190-9622
    ISSN (online) 1097-6787
    ISSN 0190-9622
    DOI 10.1016/j.jaad.2006.08.031
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1540: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Sporotrichoid Staphylococcus aureus infection in an immunosuppressed patient.

    Jacobson-Dunlop, Erick / Takiguchi, Rodd / Ward, Thomas / Barnes, Penelope / Becker, Jennifer / White, Clifton R / White, Kevin P

    Archives of dermatology

    2010  Volume 146, Issue 12, Page(s) 1435–1437

    MeSH term(s) Biopsy ; Dermatomyositis/drug therapy ; Dermatomyositis/immunology ; Diagnosis, Differential ; Female ; Humans ; Immunocompromised Host ; Immunosuppressive Agents/adverse effects ; Immunosuppressive Agents/therapeutic use ; Middle Aged ; Skin/microbiology ; Skin/pathology ; Staphylococcal Skin Infections/diagnosis ; Staphylococcal Skin Infections/immunology ; Staphylococcal Skin Infections/microbiology ; Staphylococcus aureus/isolation & purification
    Chemical Substances Immunosuppressive Agents
    Language English
    Publishing date 2010-12
    Publishing country United States
    Document type Case Reports ; Letter
    ZDB-ID 212139-6
    ISSN 1538-3652 ; 0003-987X
    ISSN (online) 1538-3652
    ISSN 0003-987X
    DOI 10.1001/archdermatol.2010.366
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui VI Zs.32: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Efalizumab therapy for atopic dermatitis causes marked increases in circulating effector memory CD4+ T cells that express cutaneous lymphocyte antigen.

    Harper, Erin G / Simpson, Eric L / Takiguchi, Rodd H / Boyd, Miranda D / Kurtz, Stephen E / Bakke, Antony C / Blauvelt, Andrew

    The Journal of investigative dermatology

    2008  Volume 128, Issue 5, Page(s) 1173–1181

    Abstract: Efalizumab is an mAb directed against CD11a, a molecule involved in T-cell activation and extravasation from blood into tissue. Ten patients with severe atopic dermatitis were treated with efalizumab for 84 days, and peripheral blood mononuclear cells ... ...

    Abstract Efalizumab is an mAb directed against CD11a, a molecule involved in T-cell activation and extravasation from blood into tissue. Ten patients with severe atopic dermatitis were treated with efalizumab for 84 days, and peripheral blood mononuclear cells were analyzed for expression of activation and adhesion markers. Efalizumab treatment led to decreases in CD11a mean fluorescence intensity (MFI) on naive, central memory, and effector memory CD4+ and CD8+ T cell subsets. MFI for CD18 was decreased in both CD4+ and CD8+ T cells. Percentages of cells positive for cutaneous lymphocyte antigen (CLA) were increased fourfold in all CD4+ and CD8+ T cell subsets. Increases in the percentages of CD4+ and CD8+ T cells expressing beta7 and CD49d were also observed. No significant changes were observed in the percentages of CD4+ and CD8+ T cells that produced either IFN-gamma or IL-4. In summary, efalizumab treatment resulted in (i) decreases in CD11a and CD18 expression in all circulating T-cell subsets and (ii) increases in the percentages of blood T cells expressing tissue homing markers (CLA, beta7, CD49d). These data suggest that blockade of T-cell extravasation into tissue is the major pathway by which efalizumab leads to improvement in cutaneous inflammation.
    MeSH term(s) Antibodies, Monoclonal/administration & dosage ; Antigens, Differentiation, T-Lymphocyte ; Antigens, Neoplasm/metabolism ; CD11a Antigen/immunology ; CD11a Antigen/metabolism ; CD18 Antigens/metabolism ; CD4 Lymphocyte Count ; CD4-Positive T-Lymphocytes/drug effects ; CD4-Positive T-Lymphocytes/immunology ; CD4-Positive T-Lymphocytes/metabolism ; CD8-Positive T-Lymphocytes/drug effects ; CD8-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/metabolism ; Dermatitis, Atopic/drug therapy ; Dermatitis, Atopic/immunology ; Humans ; Hyaluronan Receptors/metabolism ; Immunologic Memory/drug effects ; Integrin alpha4/metabolism ; Integrin beta Chains/metabolism ; Interferon-gamma/metabolism ; Membrane Glycoproteins/metabolism
    Chemical Substances Antibodies, Monoclonal ; Antigens, Differentiation, T-Lymphocyte ; Antigens, Neoplasm ; CD11a Antigen ; CD18 Antigens ; CD44 protein, human ; CTAGE1 protein, human ; Hyaluronan Receptors ; Integrin beta Chains ; Membrane Glycoproteins ; integrin beta7 ; Integrin alpha4 (143198-26-9) ; Interferon-gamma (82115-62-6) ; efalizumab (XX2MN88N5D)
    Language English
    Publishing date 2008-05
    Publishing country United States
    Document type Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 80136-7
    ISSN 1523-1747 ; 0022-202X
    ISSN (online) 1523-1747
    ISSN 0022-202X
    DOI 10.1038/sj.jid.5701169
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui VI Zs.124: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top